文献速递流行病学与生物统计临床试验与 GCP

利用替代标志物量化缩短临床试验时长的可行性

Quantifying the feasibility of shortening clinical trial duration using surrogate markers.
PubMed 文献 · Stat Med · 2021-09-02

该研究提出一种在存在删失的时间-事件结局中,基于早期标志点t0的替代标志物信息评估提前终止试验可行性的PTE指标,并给出非参数估计方法及其渐近性质。通过模拟研究和糖尿病预防计划数据,展示了糖化血红蛋白和空腹血糖预测长期糖尿病风险治疗效应的潜力。

要点

  • 提出基于早期标志点t0的PTE指标,量化利用替代标志物提前终止试验的可行性
  • 在存在删失时,结合替代标志物与事件时间信息构建个体化最优预测结局框架
  • 非参数估计方法经模拟验证,并应用于糖尿病预防计划数据评估糖化血红蛋白和空腹血糖的替代价值

核心结论

  • 提出的PTE指标可量化基于早期标志点t0的替代标志物信息提前终止试验的可行性。

研究设计与样本

  • 方法学研究,提出非参数估计框架,并通过广泛模拟研究和糖尿病预防计划真实数据应用进行验证。

主要发现

  • 模拟研究展示了估计量的有限样本性能。
  • 真实数据应用检验了糖化血红蛋白和空腹血糖预测长期糖尿病风险治疗效应的潜力。

临床怎么用

  • 在时间-事件结局且存在删失的试验中,可利用早期标志点t0的替代标志物信息评估提前终止试验的可行性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The potential benefit of using a surrogate marker in place of a long-term primary outcome is very attractive in terms of the impact on study length and cost. Many available methods for quantifying the effectiveness of a surrogate endpoint either rely on strict parametric modeling assumptions or require that the primary outcome and surrogate marker are fully observed that is, not subject to censoring. Moreover, available methods for quantifying surrogacy typically provide a proportion of treatment effect explained (PTE) measure and do not directly address the important questions of whether and how the trial can be ended earlier using the surrogate marker. In this article, we specifically address these important questions by proposing a PTE measure to quantify the feasibility of ending trials early based on endpoint information collected at an earlier landmark point t0 in a time-to-event outcome setting. We provide a framework for deriving an optimally predicted outcome for individual patients at t0 based on a combination of surrogate marker and event time information in the presence of censoring. We propose a non-parametric estimator for the PTE measure and derive the asymptotic properties of our estimators. Finite sample performance of our estimators are illustrated via extensive simulation studies and a real data application examining the potential of hemoglobin A1c and fasting plasma glucose to predict treatment effects on long term diabetes risk based on the Diabetes Prevention Program study.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Wang X, Cai T, Tian L, et al. Quantifying the feasibility of shortening clinical trial duration using surrogate markers. Stat Med. 2021. PMID: 34474500. doi:10.1002/sim.9185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。